CL2022002208A1 - Receptor de células t restringido por hla de la clase i contra ras con mutación - Google Patents

Receptor de células t restringido por hla de la clase i contra ras con mutación

Info

Publication number
CL2022002208A1
CL2022002208A1 CL2022002208A CL2022002208A CL2022002208A1 CL 2022002208 A1 CL2022002208 A1 CL 2022002208A1 CL 2022002208 A CL2022002208 A CL 2022002208A CL 2022002208 A CL2022002208 A CL 2022002208A CL 2022002208 A1 CL2022002208 A1 CL 2022002208A1
Authority
CL
Chile
Prior art keywords
cell receptor
mutation
restricted
hla class
tcr
Prior art date
Application number
CL2022002208A
Other languages
English (en)
Inventor
Levin Noam
Yoseph Rami
C Paria Biman
A Rosenberg Steven
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of CL2022002208A1 publication Critical patent/CL2022002208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Se describe un receptor de célula T (TCR) aislado y purificado, donde el TCR tiene especificidad antigénica por una secuencia de aminoácidos RAS humana mutada con una sustitución de glicina en la posición 12 con ácido aspártico presentada por una molécula de antígeno leucocitario humano (HLA) de la Clase I. También se proporcionan polipéptidos y proteínas relacionadas, así como los ácidos nucleicos relacionados, vectores de expresión recombinantes, células anfitrionas, poblaciones de células y composiciones farmacéuticas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos de tratamiento y prevención del cáncer en un mamífero.
CL2022002208A 2020-02-12 2022-08-12 Receptor de células t restringido por hla de la clase i contra ras con mutación CL2022002208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062975544P 2020-02-12 2020-02-12

Publications (1)

Publication Number Publication Date
CL2022002208A1 true CL2022002208A1 (es) 2023-06-02

Family

ID=74860472

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002208A CL2022002208A1 (es) 2020-02-12 2022-08-12 Receptor de células t restringido por hla de la clase i contra ras con mutación

Country Status (16)

Country Link
US (1) US20230080742A1 (es)
EP (1) EP4103597A1 (es)
JP (1) JP2023528112A (es)
KR (1) KR20220143867A (es)
CN (1) CN115279784A (es)
AU (1) AU2021221138A1 (es)
BR (1) BR112022015888A2 (es)
CA (1) CA3168015A1 (es)
CL (1) CL2022002208A1 (es)
CO (1) CO2022012922A2 (es)
CU (1) CU20220044A7 (es)
GB (1) GB2609760A (es)
IL (1) IL295252A (es)
MX (1) MX2022009654A (es)
TW (1) TW202140536A (es)
WO (1) WO2021163434A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230084524A (ko) * 2020-10-02 2023-06-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체
CA3209732A1 (en) 2021-02-25 2022-09-01 Drew Caldwell DENIGER Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
CA2968399A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
EA202091335A1 (ru) * 2017-12-04 2020-10-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Ограниченные hla класса i t-клеточные рецепторы против мутантного ras

Also Published As

Publication number Publication date
GB202211733D0 (en) 2022-09-28
JP2023528112A (ja) 2023-07-04
EP4103597A1 (en) 2022-12-21
WO2021163434A8 (en) 2022-09-01
KR20220143867A (ko) 2022-10-25
CU20220044A7 (es) 2023-06-13
IL295252A (en) 2022-10-01
US20230080742A1 (en) 2023-03-16
TW202140536A (zh) 2021-11-01
AU2021221138A1 (en) 2022-09-01
CA3168015A1 (en) 2021-08-19
CO2022012922A2 (es) 2022-10-21
CN115279784A (zh) 2022-11-01
BR112022015888A2 (pt) 2022-10-11
MX2022009654A (es) 2022-10-20
WO2021163434A1 (en) 2021-08-19
GB2609760A (en) 2023-02-15

Similar Documents

Publication Publication Date Title
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CL2022002208A1 (es) Receptor de células t restringido por hla de la clase i contra ras con mutación
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
AU2021203746B2 (en) T cell receptors recognizing MHC class II-restricted MAGE-A3
AR112902A1 (es) Receptores de células t restringidas a hla de clase ii contra ras mutado
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
PE20190477A1 (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos
AR106920A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia linfocítica crónica (llc) y otros tipos de cáncer
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
CL2019003311A1 (es) Nuevos péptidos (seq id no:82) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124)
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
PE20190124A1 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer
CO2018010808A2 (es) Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
CL2019003421A1 (es) Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545)
CL2023000426A1 (es) Neoantígenos ras y usos de los mismos
BR112013013158B1 (pt) composições farmacêutica para uso no tratamento de câncer, métodos in vitro para induzir célula apresentadora de antígeno, bem como vetor, e uso
Beauverger et al. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53
WO2022109258A1 (en) Methods and compositions comprising mhc class i peptides
AR122383A2 (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
KR20220052943A (ko) Mhc 클래스 ii 분자 및 이의 사용 방법
AU2022260281A1 (en) Methods and compositions comprising mhc class i peptides